Close

Novavax (NVAX) Phase 3 Prepare Trial of ResVax for Prevention of RSV Disease in Infants Doesn't Meet Primary Endpoint

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 4/19/2024

1. LVS
2. TSM
3. SPY
4. NFLX
5. CSX
6. UAL
7. ALK
8. EFX
9. TSLA
10. INFY


Go back to Novavax (NVAX) Phase 3 Prepare Trial of ResVax for Prevention of RSV Disease in Infants Doesn't Meet Primary Endpoint

Novavax (NVAX) PT Lowered to $1.50 at Oppenheimer

March 1, 2019 9:28 AM EST

Oppenheimer analyst Kevin DeGeeter lowered the price target on Novavax (NASDAQ: NVAX) to $1.50 (from $4.00) while maintaining a Outperform rating.

The analyst commented, "While we acknowledge being wrong regarding the Phase III Prepare study of ResVax for prevention of RSV disease in infants via... More

Novavax (NVAX) Resumes Trading, Down 70%

February 28, 2019 7:33 AM EST

Novavax (NASDAQ: NVAX) Resumes Trading, Down 70%

... More

Novavax (NVAX) Halted, News Pending

February 28, 2019 6:59 AM EST

Novavax (NASDAQ: NVAX) Halted, News Pending

... More